Case Report: 40-month durable deep molecular remission after blinatumomab + autologous HSCT in a high-risk B-ALL patient with HIV infection and triple risk factors

Background B-cell acute lymphoblastic leukemia (B-ALL) with human immunodeficiency virus (HIV) infection harboring concurrent high-risk genomic alterations represents an extremely rare and aggressive clinical entity with dismal prognosis. Patients living with HIV have been systematically excluded from clinical trials of bispecific T-cell engager immunotherapy, resulting in limited real-world evidence regarding safety and efficacy in this high-risk population. Case presentation On March 24, 2023, a 40-year-old man with well-controlled HIV infection presented with extreme hyperleukocytosis (309×10 9 /L), KMT2A::AFF1 (t(4;11)) rearrangement, and multiple TP53 mutations, defining a high-risk B-ALL with HIV infection and triple risk factors. After leukapheresis, cytoreduction, and vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone (VDCLP) induction chemotherapy, he achieved complete molecular remission with undetectable measurable residual disease (MRD). Antiretroviral therapy (ART) was optimized to reduce drug–drug interactions and preserve immune competence. Risk-guided blinatumomab consolidation was well tolerated and maintained deep MRD negativity without HIV virologic breakthrough. The patient subsequently received intensive consolidation and autologous hematopoietic stem cell transplantation (auto-HSCT). Longitudinal immune profiling revealed treatment phase–dependent immune remodeling, including profound and sustained B-cell aplasia. At the last follow-up on August 4, 2026, more than 40 months post-diagnosis, he remains in sustained deep molecular remission with durable HIV suppression. Conclusion This case demonstrates that ART optimization, risk-guided blinatumomab consolidation, and auto-HSCT can safely and effectively achieve durable deep molecular remission in a high-risk B-ALL patient with HIV infection and triple risk factors, although the contributions of individual treatments remain uncertain. Longitudinal immune monitoring provides novel insights into immune reconstitution and therapeutic monitoring in this ultra-high-risk population.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-17
DOI
https://doi.org/10.3389/fonc.2026.2003508
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: 40-month durable deep molecular remission after blinatumomab + autologous HSCT in a high-risk B-ALL patient with HIV infection and triple risk factors

Lingzhen Chen, Ting Zhong, Yongmin Zhang, Lanlan Jia et al.
3 links
Frontiers in Oncology
Acute Lymphoblastic Leukemia research
article

Case Report: 40-month durable deep molecular remission after blinatumomab + autologous HSCT in a high-risk B-ALL patient with HIV infection and triple risk factors

Lingzhen Chen, Ting Zhong, Yongmin Zhang, Lanlan Jia, Jiaqin Peng, Jing Ai, Manwen Tian, Junteng Chen
article en

Abstract

Background B-cell acute lymphoblastic leukemia (B-ALL) with human immunodeficiency virus (HIV) infection harboring concurrent high-risk genomic alterations represents an extremely rare and aggressive clinical entity with dismal prognosis. Patients living with HIV have been systematically excluded from clinical trials of bispecific T-cell engager immunotherapy, resulting in limited real-world evidence regarding safety and efficacy in this high-risk population. Case presentation On March 24, 2023, a 40-year-old man with well-controlled HIV infection presented with extreme hyperleukocytosis (309×10 9 /L), KMT2A::AFF1 (t(4;11)) rearrangement, and multiple TP53 mutations, defining a high-risk B-ALL with HIV infection and triple risk factors. After leukapheresis, cytoreduction, and vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone (VDCLP) induction chemotherapy, he achieved complete molecular remission with undetectable measurable residual disease (MRD). Antiretroviral therapy (ART) was optimized to reduce drug–drug interactions and preserve immune competence. Risk-guided blinatumomab consolidation was well tolerated and maintained deep MRD negativity without HIV virologic breakthrough. The patient subsequently received intensive consolidation and autologous hematopoietic stem cell transplantation (auto-HSCT). Longitudinal immune profiling revealed treatment phase–dependent immune remodeling, including profound and sustained B-cell aplasia. At the last follow-up on August 4, 2026, more than 40 months post-diagnosis, he remains in sustained deep molecular remission with durable HIV suppression. Conclusion This case demonstrates that ART optimization, risk-guided blinatumomab consolidation, and auto-HSCT can safely and effectively achieve durable deep molecular remission in a high-risk B-ALL patient with HIV infection and triple risk factors, although the contributions of individual treatments remain uncertain. Longitudinal immune monitoring provides novel insights into immune reconstitution and therapeutic monitoring in this ultra-high-risk population.

Frontiers in OncologyVol. 16
Guangzhou Eighth People's Hospital (CN), Guangzhou Medical University (CN)
Good health and well-being
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon